GSK3B and esophageal squamous cell carcinoma: Meanwhile, we found that GSK-3β inhibitor BIO-A treatment significantly disrupted the inhibited effect of suprabasin downregulation on Wnt/β-catenin pathway activity in ESCC cells, cell proliferation and anchorage-independent growth capacity (Supplementary Fig 5b–d), demonstrating that the oncogenic effect of suprabasin on Wnt/β-catenin activity in ESCC cells might be through inhibition of GSK-3β.